Spots Global Cancer Trial Database for mantle cell
Every month we try and update this database with for mantle cell cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | NCT00992992 | Lymphoma, Mantl... | Tositumomab and... | 18 Years - | GlaxoSmithKline | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | NCT00992992 | Lymphoma, Mantl... | Tositumomab and... | 18 Years - | GlaxoSmithKline | |
| CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | NCT00924326 | Primary Mediast... Diffuse, Large ... Diffuse Large B... Mantle Cell | Fludarabine Cyclophosphamid... Anti-cluster of... Aldesleukin Fludarabine Cyclophosphamid... | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| HDCT and Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma | NCT00144092 | Low Grade Lymph... | stem cell sourc... | 18 Years - 65 Years | AHS Cancer Control Alberta | |
| Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) | NCT01236391 | Mantle Cell Lym... | PCI-32765 | 18 Years - | Pharmacyclics LLC. | |
| Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma | NCT00115193 | Non-Hodgkin's L... | pegfilgrastim pegfilgrastim | 18 Years - | Amgen | |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | NCT00975975 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Chronic Lymphoc... Myelodysplasia Non-Hodgkin's L... Hodgkin's Disea... Multiple Myelom... Myelofibrosis Anemia, Aplasti... Hemoglobinuria,... | Basiliximab | 18 Years - | Indiana University | |
| SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) | NCT00076349 | Non-Hodgkin's L... | bendamustine an... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| HDCT and Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma | NCT00144092 | Low Grade Lymph... | stem cell sourc... | 18 Years - 65 Years | AHS Cancer Control Alberta | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | NCT00975975 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Chronic Lymphoc... Myelodysplasia Non-Hodgkin's L... Hodgkin's Disea... Multiple Myelom... Myelofibrosis Anemia, Aplasti... Hemoglobinuria,... | Basiliximab | 18 Years - | Indiana University | |
| SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) | NCT00076349 | Non-Hodgkin's L... | bendamustine an... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | NCT02362035 | Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk... | Acalabrutinib Pembrolizumab | 18 Years - | Acerta Pharma BV | |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | NCT02362035 | Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk... | Acalabrutinib Pembrolizumab | 18 Years - | Acerta Pharma BV | |
| Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma | NCT01148108 | Mantle Cell Lym... B Cell Lymphoma Multiple Myelom... | Canfosfamide HC... | 18 Years - | Telik | |
| Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma | NCT00115193 | Non-Hodgkin's L... | pegfilgrastim pegfilgrastim | 18 Years - | Amgen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
